المؤلفون: James L. Januzzi, Joseph M. Garasic, Scott E. Kasner, Vickie McDonald, Mark C. Petrie, Jonathan Seltzer, Michael Mauro, Kevin Croce, Ellin Berman, Michael Deininger, Andreas Hochhaus, Javier Pinilla-Ibarz, Franck Nicolini, Dong-Wook Kim, Daniel J. DeAngelo, Hagop Kantarjian, Jing Xu, Tracey Hall, Shouryadeep Srivastava, Daniel Naranjo, Jorge Cortes

المصدر: Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-25 (2022)

مصطلحات موضوعية: Acute lymphoblastic leukemia, Chronic myeloid leukemia, Safety, Tyrosine kinase inhibitor, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1756-8722

URL الوصول: https://doaj.org/article/7426e5d81482431bb46fd0f35d6ca6ed

المؤلفون: Moshe Levy, Lin Xie, Yuexi Wang, Frank Neumann, Shouryadeep Srivastava, Daniel Naranjo, Jing Xu, Qisu Zhang, Mehul Dalal

المصدر: Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100424- (2021)

مصطلحات موضوعية: Cardiovascular events, Real-world, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2468294221001222; https://doaj.org/toc/2468-2942

URL الوصول: https://doaj.org/article/60b4b76d56fc42ad8a0a421800410cd2

المؤلفون: James L. Januzzi, Joseph M. Garasic, Scott E. Kasner, Vickie McDonald, Mark C. Petrie, Jonathan Seltzer, Michael Mauro, Kevin Croce, Ellin Berman, Michael Deininger, Andreas Hochhaus, Javier Pinilla-Ibarz, Franck Nicolini, Dong-Wook Kim, Daniel J. DeAngelo, Hagop Kantarjian, Jing Xu, Tracey Hall, Shouryadeep Srivastava, Daniel Naranjo, Jorge Cortes

المصدر: Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-1 (2022)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1756-8722

URL الوصول: https://doaj.org/article/3d9cba4374b14410bb48c3c9d12799d5

المؤلفون: Hagop M. Kantarjian, Elias Jabbour, Michael Deininger, Elisabetta Abruzzese, Jane Apperley, Jorge Cortes, Charles Chuah, Daniel J. DeAngelo, John DiPersio, Andreas Hochhaus, Jeffrey Lipton, Franck E. Nicolini, Javier Pinilla‐Ibarz, Delphine Rea, Gianantonio Rosti, Philippe Rousselot, Neil P. Shah, Moshe Talpaz, Shouryadeep Srivastava, Xiaowei Ren, Michael Mauro

المصدر: American Journal of Hematology. 97:1419-1426

مصطلحات موضوعية: Pyridazines, Clinical Trials as Topic, Drug Resistance, Neoplasm, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Fusion Proteins, bcr-abl, Imidazoles, Humans, Hematology, Protein Kinase Inhibitors

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c98505c0c49205ca0ade7792449d8a9
https://doi.org/10.1002/ajh.26686

المؤلفون: Michael J. Hanley, Karthik Venkatakrishnan, Paul M. Diderichsen, Narayana I. Narasimhan, Shouryadeep Srivastava, Neeraj Gupta

المصدر: The Journal of Clinical Pharmacology. 62:555-567

مصطلحات موضوعية: Adult, Male, Oncology, medicine.medical_specialty, Bilirubin, Population, Fusion Proteins, bcr-abl, Renal function, Antineoplastic Agents, Pediatrics, Young Adult, chemistry.chemical_compound, Pharmacokinetics, hemic and lymphatic diseases, Internal medicine, Humans, Medicine, Pharmacology (medical), education, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Pharmacology, Volume of distribution, Clinical Trials as Topic, education.field_of_study, business.industry, Body Weight, Ponatinib, Imidazoles, Myeloid leukemia, Middle Aged, Healthy Volunteers, Pyridazines, Clinical trial, chemistry, Hematologic Neoplasms, Female, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::480ab272f1cc97b426f2afe25d519b21
https://doi.org/10.1002/jcph.1990

المؤلفون: Andreas Tiede, Pratima Chowdary, Margarita Timofeeva, Geoffrey Allen, Kathleen Kӧck, Martin J. Wolfsegger, Alexander Bauer, Hongyu Jeanne Jiang, Peter William Collins, Brahm Goldstein, István Takács, Shouryadeep Srivastava

المصدر: Haemophilia

مصطلحات موضوعية: safety, Adult, medicine.medical_specialty, polysialic acid, haemophilia A, 030204 cardiovascular system & hematology, Hemophilia A, Recombinant factor viii, Gastroenterology, 03 medical and health sciences, recombinant FVIII, 0302 clinical medicine, Pharmacokinetics, Internal medicine, medicine, Humans, In patient, tolerability, Clinical Haemophilia, Adverse effect, Genetics (clinical), Factor VIII, biology, business.industry, Immunogenicity, Original Articles, Hematology, General Medicine, Recombinant Proteins, Cohort, Sialic Acids, biology.protein, Original Article, Severe haemophilia A, Antibody, business, pharmacokinetics, 030215 immunology

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d90ff18203cf96bc8686d8b819eedb6d
https://doi.org/10.1111/hae.13878

المؤلفون: Mary E.R. O'Brien, Parneet K. Cheema, Christian Grohé, Enric Carcereny Costa, Nicolas Girard, Alberto Chiappori, Sally Ross, Maura Rossetti, Frederic Dubois, Joanne J. Lager, Shouryadeep Srivastava, Vamsidhar Velcheti

المصدر: Journal of Clinical Oncology. 40:TPS9158-TPS9158

مصطلحات موضوعية: Cancer Research, Oncology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::afd31d1380d5b1a416b1c91a8b35b5e9
https://doi.org/10.1200/jco.2022.40.16_suppl.tps9158

المؤلفون: Qisu Zhang, Mehul Dalal, Lin Xie, Yuexi Wang, Daniel Naranjo, Frank Neumann, Jing Xu, Moshe Yair Levy, Shouryadeep Srivastava

المصدر: Cancer Treatment and Research Communications, Vol 28, Iss, Pp 100424-(2021)

مصطلحات موضوعية: Oncology, Male, Cancer Research, medicine.medical_specialty, Population, Cardiovascular events, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Risk Factors, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Combined Chemotherapy Protocols, Nitriles, medicine, Humans, education, Protein Kinase Inhibitors, RC254-282, education.field_of_study, Aniline Compounds, Proportional hazards model, business.industry, Incidence (epidemiology), Incidence, Ponatinib, Imidazoles, Myeloid leukemia, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, United States, Pyridazines, Treatment Outcome, chemistry, Real-world, Cardiovascular Diseases, 030220 oncology & carcinogenesis, Quinolines, Female, business, Bosutinib, Tyrosine kinase, Mace, 030215 immunology, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7de7d0ffd30f150d82a9fb64ead8056
https://pubmed.ncbi.nlm.nih.gov/34198039

المؤلفون: James K. McCloskey, Andreas Hochhaus, Lori J. Maness, Michael W. Deininger, Vickie Lu, Tomasz Sacha, Christine Rojas, Charles Chuah, Moshe Talpaz, Beatriz Moiraghi, Tracey Hall, Anna G. Turkina, Jorge E. Cortes, Maria Undurraga Sutton, Hugues de Lavallade, Gianantonio Rosti, Christopher Arthur, Elza Lomaia, Michael J. Mauro, Charles A. Schiffer, Shouryadeep Srivastava, Jane F. Apperley, Carolina Pavlovsky, Jeffrey H. Lipton, Philippe Rousselot

المساهمون: Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Centre Hospitalier de Versailles André Mignot (CHV), Bristol-Myers Squibb, BMS, Pfizer, Astellas Pharma US, APUS, Novartis, Takeda Pharmaceuticals U.S.A., TPUSA, Jazz Pharmaceuticals, Daiichi-Sankyo, Sun Pharma, Conflict-of-interest disclosure: J.C. has been a consultant to and received research funding from Bristol Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Astellas, Novartis, Pfizer, Takeda, and BioPath Holdings, has received research funding from Sun Pharma, Telios, Arog, Merus, and Immunogen, has held membership on the board of directors or advisory committee of BioPath Holdings, and has been a consultant to Amphivena Therapeutics and BiolineRx. J.A. has received honoraria and research funding and is on the speakers bureaus of Incyte and Pfizer, and has received honoraria and served on the speakers bureaus of Bristol Myers Squibb and Novartis. E.L. has served on the speakers bureaus of Novartis and Pfizer, and has received travel and accommodation reimbursement from Novartis, Pfizer, and Bristol Myers Squibb. B.M. has served on the speakers bureaus of Novartis, Pfizer, and Takeda. M.U.S. has served on the advisory boards of AbbVie, Janssen, Novartis, Pfizer, and Roche and on the speakers bureaus of Janssen, Novartis, and Pfizer. C.C. has received honoraria from Novartis and Korea Otsuka Pharmaceutical, received honoraria and research funding from Bristol Myers Squibb, and received travel reimbursement and research funding from Pfizer. T.S. has been a consultant to, has received honoraria from, and has served on the speakers bureaus of Bristol Myers Squibb, Novartis, Pfizer, and Incyte, and has been a consultant to and received honoraria from Adamed. J.H.L. has been a consultant to and has received research funding from Bristol Myers Squibb, Ariad, Pfizer, and Novartis. C.A.S. has been a consultant to Bristol Myers Squibb and Novartis, and has received research funding from Takeda. A.H. has received honoraria and research funding from Bristol Myers Squibb, Novartis, and Pfizer, research funding from Incyte and Merck Sharp & Dohme, and honoraria from Takeda. P.R. has been a consultant to and has received funding from Incyte and Pfizer, and has been a consultant to Bristol Myers Squibb, Novartis, and Takeda. G.R. has received research funding from and served on the speakers bureau for Pfizer, and has served on the speakers bureaus of Bristol Myers Squibb, Incyte, and Novartis. H. de L. has received honoraria and research funding from Bristol Myers Squibb and Incyte, and honoraria from Pfizer and Novartis. C.R. has received personal fees from AstraZeneca, Roche, Novartis, and Janssen. M.T. holds membership on the board of directors or advisory committees of Bristol Myers Squibb and Constellation Pharmaceuticals, has received research funding from Takeda and Novartis, and has been a consultant to IMAGO. M.M. has been a consultant to and has received honoraria, reimbursement of travel, accommodation and expenses, and research funding from Bristol Myers Squibb, Novartis, Takeda, and Pfizer, and research funding from Sun Pharma/SPARC. T.H. and V.L. are employees of Millennium Pharmaceuticals. S.S. is an employee of Takeda. M.D. is a consultant to, holds a membership on the board of directors or advisory committees of, was part of a study management committee of, and received research funding from Blueprint Medicines Corporation, is a consultant to Fusion Pharma, Medscape, and DisperSol, is a consultant to, has held membership on the board of directors or advisory committees of, and has received research funding from Takeda, is a consultant to and holds membership on the board of directors or advisory committee of Sangamo, is a consultant to and received research funding from Novartis, is a consultant to and received honoraria and research funding from Incyte, and has received research funding from SPARC, DisperSol, and the Leukemia and Lymphoma Society. C.P., A.T., C.K.A., J. M., and L.M. declare no competing financial interests., Professional medical writing assistance was provided by Duprane Young of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, and funded by Millennium Pharmaceuticals, Inc.

المصدر: Blood
Blood, American Society of Hematology, 2021, 138 (21), pp.2042-2050. ⟨10.1182/blood.2021012082⟩

مصطلحات موضوعية: Adult, Male, Oncology, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Immunology, Population, Fusion Proteins, bcr-abl, Phases of clinical research, Antineoplastic Agents, Biochemistry, Young Adult, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, hemic and lymphatic diseases, medicine, Clinical endpoint, Humans, Prospective cohort study, education, Protein Kinase Inhibitors, Aged, 030304 developmental biology, Aged, 80 and over, 0303 health sciences, education.field_of_study, Dose-Response Relationship, Drug, business.industry, Ponatinib, Imidazoles, Cell Biology, Hematology, Middle Aged, Dose-ranging study, 3. Good health, Pyridazines, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, Relative risk, Leukemia, Myeloid, Chronic-Phase, Cohort, Female, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a34c2964afaa4b8a859b711a88959b77
https://ruj.uj.edu.pl/xmlui/handle/item/284884

المؤلفون: Jorge E. Cortes, Jane F. Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues De Lavallade, Michael J. Mauro, Tracey Hall, Vickie Lu, Shouryadeep Srivastava, Michael W. Deininger

المصدر: Clinical Lymphoma Myeloma and Leukemia. 21:S223

مصطلحات موضوعية: Cancer Research, Oncology, Hematology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::0ff8e4576859eb1094b37acb4b2cccb5
https://doi.org/10.1016/s2152-2650(21)01408-7